0LW Stock Overview
Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Neovacs S.A. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €5.00 |
52 Week High | €160,000.00 |
52 Week Low | €5.00 |
Beta | 0.58 |
1 Month Change | 0% |
3 Month Change | 0% |
1 Year Change | -100.00% |
3 Year Change | -100.00% |
5 Year Change | -100.00% |
Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
0LW | DE Biotechs | DE Market | |
---|---|---|---|
7D | 0% | 2.1% | 1.9% |
1Y | -100.0% | 37.0% | 7.3% |
Return vs Industry: 0LW underperformed the German Biotechs industry which returned -23.7% over the past year.
Return vs Market: 0LW underperformed the German Market which returned -2.6% over the past year.
Price Volatility
0LW volatility | |
---|---|
0LW Average Weekly Movement | n/a |
Biotechs Industry Average Movement | 5.8% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.1% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 0LW has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 0LW's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1993 | 23 | Hugo Brugiere | https://www.neovacs.com |
Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for autoimmune diseases using its Kinoid technology. The company’s product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of lupus erythematosus; and Phase IIa clinical trial for the treatment of dermatomyositis; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies.
Neovacs S.A. Fundamentals Summary
0LW fundamental statistics | |
---|---|
Market cap | €703.37k |
Earnings (TTM) | -€5.00m |
Revenue (TTM) | €53.48k |
13.2x
P/S Ratio-0.1x
P/E RatioIs 0LW overvalued?
See Fair Value and valuation analysisEarnings & Revenue
0LW income statement (TTM) | |
---|---|
Revenue | €53.48k |
Cost of Revenue | €3.63m |
Gross Profit | -€3.58m |
Other Expenses | €1.42m |
Earnings | -€5.00m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -14.21 |
Gross Margin | -6,686.05% |
Net Profit Margin | -9,343.60% |
Debt/Equity Ratio | 3.0% |
How did 0LW perform over the long term?
See historical performance and comparison